Product Development and Launch - The company has acquired a pain relief medication for orthopedic treatment, expected to launch in 2024[4] - The company is currently representing two osteoporosis treatment medications, with one service contract signed and promotion underway[4] - A new orthopedic health brand will be launched this year to enhance market penetration and brand value[4] - A total of HKD 1,500,000 is allocated for the development of bone health products, with one R&D project requiring HKD 2,900,000 expected to be utilized by the end of 2026[12] Business Expansion - The company has established new subsidiaries in Hainan and Beijing to expand its business operations[8] - The company has established a cross-border health platform with three proprietary products and over ten international brands, currently selling on major e-commerce platforms[18] - The company is focusing on the orthopedic health sector, leveraging national policies to create new value for shareholders[8] Partnerships and Collaborations - The company has partnered with a data-driven AI diagnostic company to promote osteoporosis diagnostic equipment and services in the Asia-Pacific region[10] - The company holds a 25.3% stake in Beijing Kangchen Biotechnology Co., continuing investment in A-share listed enterprises[17] Financial Management - The company plans to utilize HKD 2,000,000 for processing fees related to orthopedic drug production by the end of 2024[12] - On September 21, 2023, the company completed a placement of 263,073,000 new shares at a price of HKD 0.05 per share, raising approximately HKD 12 million after expenses[21] - The board has no intention to change the planned use of the net proceeds from the placement as of the report date[23] - The expected timeline for utilizing the net proceeds is based on the company's best estimates and may change according to market conditions[23] Service Provision and Market Position - The company aims to establish the largest digital medical information service provider in the bone health sector in the country[19] - As of the first half of 2024, the company has already provided services to one enterprise and is gradually expanding its user base[19]
泰凌医药(01011) - 2024 - 年度业绩